<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02758132</url>
  </required_header>
  <id_info>
    <org_study_id>Rosser 2015-1</org_study_id>
    <nct_id>NCT02758132</nct_id>
  </id_info>
  <brief_title>Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases</brief_title>
  <official_title>Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases: Clinical Testing and Feasibility of a Serum-based Metabolomics Profile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Hawaii</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Hawaii</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a correlative study to characterize serum metabolites associated with bone
      deposition, growth and turnover in patients with newly diagnosed metastatic CRPC who are not
      currently receiving bone targeting agents.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Low accruals
  </why_stopped>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">September 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure change in serum-based metabolites associated with bone deposition, growth and turnover in patients who have CRPC with clinical evidence of metastatic disease to the bone, all using gas chromatography-time-of-flight mass spectrometry (GC-TOFMS).</measure>
    <time_frame>Prior to Registration, Registration, Day 1 of cycle 4 and 13</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measure time (months) to skeletal related event (SRE) of patients on therapy</measure>
    <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure time (months) to progression-free survival of patients on therapy</measure>
    <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measure time (months) to duration of response of patients on therapy.</measure>
    <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Measure change in technetium bone scintigraphy on therapy via technetium bone scintigraphy or sodium fluoride (NaF) PET/CT imaging</measure>
    <time_frame>Prior to Registration, Day 1 of cycle 4 and 13, Post-Treatment Follow-up (up to 5 years post treatment)</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Measure change in treatment response via RECIST criteria</measure>
    <time_frame>Day 1 of each S.O.C cycle (28 days), and until confirmed radiographic disease progression AND initiation of other standard OR investigational agents for prostate cancer, up to 5 years post treatment</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the effect of therapy on quality of life (QoL) in patients via QoL questionnaire.</measure>
    <time_frame>Prior to Registration, Registration, Day 1 of cycle 4 and 13</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Evaluate the effect of therapy on narcotic use in patients on therapy via case report forms.</measure>
    <time_frame>Prior to Registration, Registration, Day 1 of cycle 4 and 13</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Alliance A031201</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Denosumab plus enzalutamide, abiraterone and prednisone</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Denosumab plus enzalutamide alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Denosumab</intervention_name>
    <description>One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.</description>
    <arm_group_label>Alliance A031201</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide</intervention_name>
    <description>160 mg enzalutamide by mouth daily</description>
    <arm_group_label>Alliance A031201</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abiraterone</intervention_name>
    <description>1000 mg abiraterone by mouth daily</description>
    <arm_group_label>Alliance A031201</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>5 mg prednisone by mouth twice daily</description>
    <arm_group_label>Alliance A031201</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologic proof of adenocarcinoma of the prostate with clinical evidence of
             metastatic disease to the bone.

          -  Castrate resistant progression of prostate carcinoma, as shown by:

               -  Serum testosterone level &lt;50 ng/dL or prior bilateral orchiectomy. Treatment to
                  maintain castrate levels of testosterone should continue, and

                    -  Either symptomatic progression, or, if patient is asymptomatic then a rising
                       serum PSA in two occasions at least 1 week apart, with minimum pre-treatment
                       serum PSA of 5 ng/dL.

          -  Patients with nodal disease are eligible.

          -  Bi-dimensionally measurable disease within the bone.

          -  Life expectancy of at least 12 weeks.

          -  ECOG Performance status &lt; 2

          -  Adequate:

               -  Bone marrow function; absolute neutrophil count &gt; 1,500 mm3, platelet count of &gt;
                  100,000 mm3 and hemoglobin &gt; 9.0 gm/dl.

               -  Hepatic function; SGOT/SGPT and conjugated bilirubin less than twice the upper
                  limit of normal.

               -  Renal function; serum creatinine ≤ 2 mg/dL (or, if creatinine &gt; 2 mg/dL, then a
                  creatinine clearance of at least 35 ml/min (measured or estimated by the Cockroft
                  formula:

        CLcr = [(140-age) x wt (kg)]/[72 x serum creatinine (mg/dL)].

          -  No evidence of coagulopathy as indicated by PT &lt; 1.5X upper limit of normal.

          -  Serum calcium (corrected) from 8 to11.5 mg/dL (2 to 2.9 mmol/L) - Patients must sign
             an informed consent indicating that they are aware of the investigational nature of
             the study.

        Exclusion Criteria:

          -  Patients with variant histologies (e.g., ductal or small cell carcinoma).

          -  Patients with visceral disease are ineligible.

          -  Patients who have had prior Sipuleucel-T, docetaxel, cabazitaxel, abiraterone or
             enzalutamide as a single agent, or in combination therapy.

          -  Concurrent cancer chemotherapy, radiotherapy or surgery.

          -  Concurrent serious infection.

          -  Life threatening illness (e.g., congestive heart failure, uncontrolled angina or
             myocardial infarction in the prior six months).

          -  Hypertension uncontrolled by medication.

          -  Patients who are known to require invasive dental procedures.

          -  No known or suspected brain metastases (NOTE: patients with treated epidural disease
             are allowed)

          -  Administration of any investigational drug within 28 days prior to receipt of
             denosumab.

          -  Age ≤ 18 years of age
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of Hawaii Cancer Center</name>
      <address>
        <city>Honolulu</city>
        <state>Hawaii</state>
        <zip>96813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 11, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 2, 2016</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Castrate-resistant prostate cancer with bone metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Denosumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

